Abbott (NYSE:ABT) is facing an FDA warning letter alleging quality system regulation violations related to FreeStyle Libre ...
Abbott Laboratories is cited for four key alleged violations related to the production of its Freestyle Libre continuous ...
Abbott has been hit with a slew of complaints from the FDA in a warning letter related to its continuous glucose monitor (CGM ...
The FDA has escalated the recall of specific Abbott FreeStyle Libre 3 and 3 Plus CGMs to Class I, the highest level of ...
The Food and Drug Administration (FDA) has now identified the previous recall of certain FreeStyle Libre glucose monitor ...
Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results